← 產業報告目錄
Peptide CDMO (Pharmaceutical) Market Size, Share & Trends Analysis Report By Scale of Operation (Preclinical / Clinical, Commercial), By Method Used, (Chemical Synthesis Method, Non-Chemical Synthesis Method), By Applications, By Synthesis Types, By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-27頁數 175報告編號 INSIGHTACE-629576edb6
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide Peptide CDMO (Pharmaceutical) Market is forecasted to register a CAGR of 10.4%.
The Peptide CDMO (Pharmaceutical) sector involves bioactive molecules that bind to specific cell surface receptors, such as g protein-coupled receptors (gpcrs) or ion channels, where they trigger intracellular effects. This domain has witnessed notable transformation owing to technological breakthroughs and shifting healthcare dynamics.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold notable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and growing investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide CDMO (Pharmaceutical) Market Snapshot
Chapter 4. Global Peptide CDMO (Pharmaceutical) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis
5.1. By Scale of Operation & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 for the following By scale of operation:
5.2.1. Preclinical / Clinical
5.2.2. Commercial
Chapter 6. Market Segmentation 2: By Applications Estimates & Trend Analysis
6.1. By Method Used & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Method Used:
6.2.1. Chemical Synthesis Method
6.2.2. Non-Chemical Synthesis Method
Chapter 7. Market Segmentation 3: By Synthesis Types Estimates & Trend Analysis
7.1. By Applications & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Applications:
7.2.1. Peptide Supplements
7.2.2. Peptide Vaccines
7.2.3. Peptides as Radio-Theranostic Agents
7.2.4. Cell Penetrating Peptides (CPPs)
7.2.5. Affinity Ligands
7.2.6. Protein Mimics
Chapter 8. Market Segmentation 4: By Synthesis Types Estimates & Trend Analysis
8.1. By Synthesis Types & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Synthesis Types
8.2.1. LPPS
8.2.2. SPPS
8.2.3. Mixed Phase
Chapter 9. Peptide CDMO (Pharmaceutical) Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034
9.1.2. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts By Method Used, 2021-2034
9.1.3. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Applications, 2021-2034
9.1.4. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Synthesis Types, 2021-2034
9.1.5. North America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2. Europe
9.2.1. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, 2021-2034
9.2.2. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, 2021-2034
9.2.3. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, 2021-2034
9.2.4. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts by Synthesis Types, 2021-2034
9.2.5. Europe Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, 2021-2034
9.3.2. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, 2021-2034
9.3.3. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, 2021-2034
9.3.4. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts by Synthesis Types, 2021-2034
9.3.5. Asia Pacific Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by country, 2023-2031
9.4. Latin America
9.4.1. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
9.4.2. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, (US$ Million) 2021-2034
9.4.3. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, (US$ Million) 2021-2034
9.4.4. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) Estimates and Forecasts by Synthesis Types, 2021-2034
9.4.5. Latin America Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by Country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
9.5.2. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Method Used, (US$ Million) 2021-2034
9.5.3. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) By Applications, (US$ Million) 2021-2034
9.5.4. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) estimates and forecasts by Synthesis Types, 2021-2034
9.5.5. Middle East & Africa Peptide CDMO (Pharmaceutical) Market Revenue (US$ Million) by Country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. AmbioPharm
10.2.2. Auspep
10.2.3. Bachem
10.2.4. BCN Peptide
10.2.5. CPC Scientific
10.2.6. CBL- Chemical and Biopharmaceutical Laboratories
10.2.7. Creative Peptides
10.2.8. Chinese Peptide
10.2.9. CSBio
10.2.10. Corden Pharma
10.2.11. PolyPeptide
10.2.12. Hybio Pharmaceutical
10.2.13. Peptide Institute
10.2.14. Pepscan
10.2.15. Almac
10.2.16. vivitide
10.2.17. CreoSalus Inc
10.2.18. ScinoPharm
10.2.19. Senn Chemicals
10.2.20. Wuxi AppTec
10.2.21. Olon
10.2.22. Belyntic
10.2.23. Ferring Pharma
10.2.24. Numaferm
10.2.25. Hybio Pharmaceutical
10.2.26. Provepharm life solutions
10.2.27. Enzene Biosciences
10.2.28. Ardena Holding
10.2.29. Stelis Biopharma
10.2.30. Piramal Pharma
10.2.31. Space Peptides Pharmaceutical
10.2.32. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們